AG-TICAGRELOR TABLET

Country: Canada

Language: English

Source: Health Canada

Active ingredient:

TICAGRELOR

Available from:

ANGITA PHARMA INC.

ATC code:

B01AC24

INN (International Name):

TICAGRELOR

Dosage:

90MG

Pharmaceutical form:

TABLET

Composition:

TICAGRELOR 90MG

Administration route:

ORAL

Units in package:

100

Prescription type:

Prescription

Product summary:

Active ingredient group (AIG) number: 0152934001; AHFS:

Authorization status:

APPROVED

Authorization date:

2023-04-13

Summary of Product characteristics

_AG-Ticagrelor (Ticagrelor Tablets) Product Monograph Page _
_1_
_ of _
_63_
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AG-TICAGRELOR
Ticagrelor Tablets
60 and 90 mg, Oral
Ph. Eur.
Platelet Aggregation Inhibitor
Angita Pharma Inc.
1310 rue Nobel
Boucherville, Quebec
J4B 5H3, Canada
Date of Preparation:
APR 12, 2023
Submission Control Number: 273577
_AG-Ticagrelor (Ticagrelor Tablets) Product Monograph Page _
_2_
_ of _
_63_
_ _
RECENT MAJOR LABEL CHANGES
N/A
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................. 4
1
INDICATIONS
.................................................................................................................
4
1.1
Pediatrics
...............................................................................................................
4
1.2
Geriatrics
...............................................................................................................
4
2
CONTRAINDICATIONS
..................................................................................................
4
4
DOSAGE AND ADMINISTRATION
................................................................................
5
4.1
Dosing Considerations
...........................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
...................................................... 5
4.4
Administration
........................................................................................................
7
4.5
Missed Dose
..........................................................................................................
7
5
OV